Finoriq research workspace
Aligos Therapeutics, Inc. (ALGS) SEC Filings & Filing Highlights
Aligos Therapeutics, Inc. also develops pevifoscorvir sodium, a capsid assembly modulator, which. Review ALGS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Company
- Aligos Therapeutics, Inc. (ALGS)
- Ticker
- ALGS
- Market Cap
- $32.5M
- Latest Price
- $5.25
- Industry
- Biotech & Pharma
Aligos Therapeutics, Inc. (ALGS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aligos Therapeutics, Inc. (ALGS).
| Event | Form | Date |
|---|---|---|
| Broker Non-VotesAt the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the Proxy Statement... | 8-K5.07 | 2026-06-26 |
| On June 25, 2026, Aligos Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockhol...On June 25, 2026, Aligos Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). As further desc... | 8-K5.02 | 2026-06-26 |
| On May 7, 2026, the Registrant issued a press release, a copy of which is attached hereto as Ex...On May 7, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by ref... | 8-K2.02 | 2026-05-07 |
| Aligos Therapeutics, Inc.: Material agreementOn April 16, 2026, Aligos Therapeutics, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Xiamen Amoytop... | 8-K1.01 | 2026-04-21 |
| Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepat...Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with... | 8-K8.01 | 2026-04-14 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.